> Mission Therapeutics landed a deal with AbbVie. The agreement, financial details of which remain a secret, gives AbbVie an option on drugs against four Alzheimer’s and Parkinson’s targets. Release
> Redx Pharma unveiled a fibrosis drug it hopes to move into the clinic in 2020. The drug is an oral porcupine inhibitor. Statement
> Reti Pharma secured €1.3 million ($1.5 million) from the Novo Nordisk Foundation’s BioInnovation Institute to ready retinal detachment drug RP001 for a clinical proof-of-concept study. Release
> Transgene posted phase 1 data on its chronic hepatitis B drug TG1050. The trial hit its primary safety endpoint. Statement
> NorthSea Therapeutics presented preclinical data on its lead candidate icosabutate in NASH. The Forbion-backed biotech plans to start a phase 2b trial of the drug next year. Release